Samsung Bioepis occupies 25% of Avastin mkt 1yr since launch

By | translator Alice Kang

22.11.29 12:02:25

가나다라 0

Onbevzi’s Q3 sales record KRW 6.4 billion... sales of original Avastin fall 35% in a year

Market share of biosimilar to increase further with the release of Alymsis·Vegzelma in December

Intense 4-way race including Avastin expected to start in earnest

Samsung Bioepis’s Avastin (bevacizumab) biosimilar ‘Onbevzi’ is enjoying its market preoccupation effect. In only one year since its release, the share of its similar reached nearly 25% in the market. With Alvogen and Celltrion’s biosimilars succeeding to be released with reimbursement from the next month, the competition between biosimilars is expected to intensify further.

Onbevzi enjoys ‘first mover’ benefit... original’s sales reduced 35%

▲Pic of Avastin

On the 29th, according to the market research institution IQVIA, Samsung Bioepis’s Onbevzi raised sales of KRW 6.4 billion in Q3 this year. Such sales have been made only 1 year since its release.

Onbevzi quickly took

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)